PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab

Transl Cancer Res. 2023 Apr 28;12(4):705-708. doi: 10.21037/tcr-23-52. Epub 2023 Apr 3.

Authors

Lukas Käsmann^{1

2

3}, Alexander Nieto¹, Julian Taugner¹, Farkhad Manapov^{1

2

3}

Affiliations

¹ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
² German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany.
³ German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.

No abstract available

Keywords: Non-small cell lung cancer (NSCLC); PD-L1 expression; durvalumab; predictive biomarker; stage III.

Publication types

Editorial
Comment